NCT02090127: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient |
|
|
| No Longer Available | N/A | | US | ficlatuzumab, AV-299, SCH 900105 | AVEO Pharmaceuticals, Inc. | Mullerian Mixed Tumor of Ovary | | | | |
| Enrolling by invitation | N/A | 10000 | Europe | Screening for cervical cancer | Tampere University, FinnMedi Oy, GlaxoSmithKline | Uterine Cervical Cancer | 12/24 | 12/24 | | |